


Fact Sheet: Medicare Part B Inflation Rebates for Calendar Year 2023



The Centers for Medicare and Medicaid Services (CMS) assesses inflation rebates to drug manufacturers that raise the prices of certain Medicare Part B drugs faster than the rate of inflation. This fact sheet summarizes the round of invoices that CMS delivered to drug manufacturers in each applicable quarter in calendar year 2023. In general, the rebate amount is equal to the number of units of the Part B rebatable drug furnished during the quarter multiplied by the difference between the specified amount¹ and the inflation-adjusted payment amount. For further information on how Part B rebatable drugs are identified and the Part B rebate amount is calculated, refer to 42 CFR § 427.101 and 42 CFR §§ 427.300-427.402, respectively.

The following table contains the billing and payment codes for which manufacturer(s) owed a Part B rebate and the total Part B rebate amounts owed for all four applicable quarters in calendar year 2023. In accordance with 42 CFR § 427.502(c)(1)(iii), no regular reconciliation will be conducted of the rebate amounts owed in calendar year 2023. Total Part B rebates owed to Medicare for all four applicable quarters in 2023 amount to more than **\$14 million**. Inflation rebate funds are deposited in the Federal Supplementary Medical Insurance Trust Fund as required by law.

¹ The applicable calendar quarter specified amount is calculated as described in [42 CFR § 427.302\(b\)](#).

Rebate Amounts Owed for Calendar Year 2023, as of September 2025

Billing and Payment Code	Code Description	Part B Rebate Owed
J9177	INJ ENFORT VEDO-EJFV 0.25MG	\$3,728,545.20
J0897	DENOSUMAB INJECTION	\$3,121,861.29
J0775	COLLAGENASE, CLOST HIST INJ	\$2,466,765.23
J9047	INJECTION, CARFILZOMIB, 1 MG	\$868,096.37
J9042	BRENTUXIMAB VEDOTIN INJ	\$854,671.27
J2796	ROMIPLOSTIM INJECTION	\$839,373.31
J3145	TESTOSTERONE UNDECANOATE 1MG	\$735,460.72
J9039	INJECTION, BLINATUMOMAB	\$448,744.67
J9303	PANITUMUMAB INJECTION	\$323,646.68
Q5104	INJECTION, RENFLEXIS	\$233,324.59
J0561	PENICILLIN G BENZATHINE INJ	\$81,097.92
J9325	INJ TALIMOGENE LAHERPAREPVEC	\$72,373.22
J2860	INJECTION, SILTUXIMAB	\$62,092.45
J0584	INJECTION, BUROSUMAB-TWZA 1M	\$59,277.67
J9061	INJ, AMIVANTAMAB-VMJW	\$45,190.24
J2502	INJ, PASIREOTIDE LONG ACTING	\$38,302.12
J1555	INJ CUVITRU, 100 MG	\$37,338.35
J1551	INJ CUTAQUIG 100 MG	\$32,011.42
J1640	HEMIN, 1 MG	\$26,392.01
J1950	LEUPROLIDE ACETATE /3.75 MG	\$23,343.82
J2820	SARGRAMOSTIM INJECTION	\$19,439.90
J9307	PRALATREXATE INJECTION	\$16,042.25
J0850	CYTOMEGALOVIRUS IMM IV /VIAL	\$14,076.30
J9266	PEGASPARGASE INJECTION	\$8,614.78
C9482	SOTALOL HYDROCHLORIDE IV	\$6,255.52
J1645	DALTEPARIN SODIUM	\$4,578.43
J9262	INJ, OMACETAXINE MEP, 0.01MG	\$4,013.04
J0558	PENG BENZATHINE/PROCAINE INJ	\$3,730.38
J2850	INJ SECRETIN SYNTHETIC HUMAN	\$3,015.21
J1456	INJ, FOSAPREPITANT (TEVA)	\$2,704.47
J1670	TETANUS IMMUNE GLOBULIN INJ	\$2,086.48
J2265	MINOCYCLINE HYDROCHLORIDE	\$1,262.21
J1746	INJ., IBALIZUMAB-UIYK, 10 MG	\$1,017.11
J2315	NALTREXONE, DEPOT FORM	\$381.17
J0888	EPOETIN BETA NON ESRD	\$333.85
J7504	LYMPHOCYTE IMMUNE GLOBULIN	\$310.03

Rebate Amounts Owed for Calendar Year 2023, as of September 2025 (Contd.)

Billing and Payment Code	Code Description	Part B Rebate Owed
J2184	INJ, MEROPENEM (B. BRAUN)	\$204.79
J0898	ARGATROBAN NONESRD (AUROMED)	\$204.31
J0291	INJ., PLAZOMICIN, 5 MG	\$196.23
90396	VARICELLA-ZOSTER IMMUNE GLOBULIN, HUMAN, FOR INTRAMUSCULAR USE	\$99.39
J8655	ORAL NETUPITANT, PALONOSETRO	\$40.87
	TOTAL	\$14,186,515.27